INTRODUCTION
Onychomycosis—a chronic and recurring fungal infection of the fingernails or toenails—can occur in children, ranging in prevalence from 0.35%–5.5% worldwide.1 Though less common in children than adults,1 onychomycosis has been reported to be responsible for approximately 15% of all nail dystrophies in children.2 Onychomycosis of the toenail can result in permanent toenail deformity, discomfort, and interference with wearing shoes and walking.3
Treatment of onychomycosis is challenging due to the deep location of the infection under the densely keratinized nail plate and can require systemic antifungals for prolonged periods of time.4 However, parents and healthcare practitioners are hesitant to treat young children with a systemic drug that requires laboratory monitoring and can have systemic toxicities5; additionally, oral antifungal agents are not FDA approved for onychomycosis in children. Due to their thinner, faster-growing nails, children are theoretically more likely to respond to topical monotherapy than adults and are therefore good candidates for topical antifungal therapy.5 Currently, there are 3 topical treatments approved for pediatric use: ciclopirox 8% in children ≥12 years of age (generic), tavaborole 5% (Kerydin®, PharmaDerm, Melville, NY) in children ≥6 years of age, and efinaconazole 10% (Jublia®, Ortho Dermatologics, Bridgewater, NJ) in children ≥6 years of age.
Treatment of onychomycosis is challenging due to the deep location of the infection under the densely keratinized nail plate and can require systemic antifungals for prolonged periods of time.4 However, parents and healthcare practitioners are hesitant to treat young children with a systemic drug that requires laboratory monitoring and can have systemic toxicities5; additionally, oral antifungal agents are not FDA approved for onychomycosis in children. Due to their thinner, faster-growing nails, children are theoretically more likely to respond to topical monotherapy than adults and are therefore good candidates for topical antifungal therapy.5 Currently, there are 3 topical treatments approved for pediatric use: ciclopirox 8% in children ≥12 years of age (generic), tavaborole 5% (Kerydin®, PharmaDerm, Melville, NY) in children ≥6 years of age, and efinaconazole 10% (Jublia®, Ortho Dermatologics, Bridgewater, NJ) in children ≥6 years of age.